Lyell Immunopharma Files 8-K on Shareholder Vote Matters
Ticker: LYEL · Form: 8-K · Filed: Jun 14, 2024 · CIK: 1806952
| Field | Detail |
|---|---|
| Company | Lyell Immunopharma, Inc. (LYEL) |
| Form Type | 8-K |
| Filed Date | Jun 14, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Lyell Immunopharma held a shareholder vote. Details TBD.
AI Summary
Lyell Immunopharma, Inc. filed an 8-K on June 14, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the vote's outcome or the proposals presented.
Why It Matters
This filing indicates that Lyell Immunopharma held a shareholder vote, which could signal significant corporate actions or changes in governance. Investors should look for further disclosures to understand the implications.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose any immediate financial or operational risks.
Key Players & Entities
- Lyell Immunopharma, Inc. (company) — Registrant
- June 14, 2024 (date) — Date of Report
FAQ
What specific matters were submitted for a vote to Lyell Immunopharma's security holders?
The filing does not specify the exact proposals or matters that were submitted for a vote.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 14, 2024.
What is Lyell Immunopharma's state of incorporation?
Lyell Immunopharma, Inc. is incorporated in Delaware.
What is the principal executive office address for Lyell Immunopharma?
The principal executive offices are located at 201 Haskins Way, South San Francisco, California, 94080.
What is the SIC code for Lyell Immunopharma?
The Standard Industrial Classification (SIC) code is 2834, for Pharmaceutical Preparations.
Filing Stats: 654 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2024-06-14 16:07:01
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share LYEL The Nasdaq
Filing Documents
- d855288d8k.htm (8-K) — 34KB
- 0001193125-24-161601.txt ( ) — 150KB
- lyel-20240614.xsd (EX-101.SCH) — 3KB
- lyel-20240614_lab.xml (EX-101.LAB) — 17KB
- lyel-20240614_pre.xml (EX-101.PRE) — 11KB
- d855288d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lyell Immunopharma, Inc. Date:June 14, 2024 By: /s/ Matthew Lang Matthew Lang Chief Business Officer